Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 74 of 74 entries
View as:

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Phase: N/A Priority: Normal
NCT ID: NCT04625153 Org: User:
Start: 05/13/21 End: 12/31/25 Due: 12/31/26

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06178159 Org: User:
Start: 11/28/23 End: 06/30/25 Due: 06/30/26

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06389006 Org: User:
Start: 04/29/24 End: 12/31/26 Due: 12/31/27

Study of Telitacicept in Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT05737160 Org: User:
Start: 03/28/23 End: 12/12/24 Due: 12/12/25

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03500380 Org: User:
Start: 04/24/18 End: 12/31/24 Due: 12/31/25

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04190823 Org: User:
Start: 03/15/20 End: 12/30/23 Due: 12/30/24

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT03777254 Org: User:
Start: 01/07/19 End: 08/20/19 Due: 08/20/20

Evaluation of RC28-E Injection in Diabetic Retinopathy

Phase: N/A Priority: Normal
NCT ID: NCT04782128 Org: User:
Start: 05/25/21 End: 07/31/24 Due: 07/31/25

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06173037 Org: User:
Start: 01/19/24 End: 12/31/26 Due: 12/31/27

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)

Phase: N/A Priority: Normal
NCT ID: NCT06456580 Org: User:
Start: 07/17/24 End: 10/31/27 Due: 10/31/28

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05687526 Org: User:
Start: 05/25/23 End: 10/31/25 Due: 10/31/26

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06642545 Org: User:
Start: 02/10/25 End: 10/01/27 Due: 10/01/28

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05867303 Org: User:
Start: 06/05/23 End: 12/31/24 Due: 12/31/25

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06227156 Org: User:
Start: 04/08/24 End: 06/30/26 Due: 06/30/27

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05205850 Org: User:
Start: 03/03/22 End: 12/01/25 Due: 12/01/26

A Phase I /IIa Study of RC88-ADC in Subjects with Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04175847 Org: User:
Start: 04/14/20 End: 12/31/25 Due: 12/31/26

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02881138 Org: User:
Start: 03/01/16 End: 07/15/20 Due: 07/15/21

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06016062 Org: User:
Start: 09/14/23 End: 12/31/25 Due: 12/31/26

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05821933 Org: User:
Start: 09/07/23 End: 09/01/26 Due: 09/01/27

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04078386 Org: User:
Start: 11/21/19 End: 10/26/21 Due: 10/26/22

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT05885503 Org: User:
Start: 06/08/23 End: 06/30/26 Due: 06/30/27

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03809013 Org: User:
Start: 01/07/19 End: 06/05/23 Due: 06/05/24

A Study of Telitacicept in Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT05680480 Org: User:
Start: 04/17/23 End: 01/31/26 Due: 01/31/27

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Phase: N/A Priority: Normal
NCT ID: NCT05940896 Org: User:
Start: 06/29/23 End: 02/28/27 Due: 02/28/28